Clinical pharmacokinetics of cyclophosphamide - PubMed
Knowledge of the pharmacokinetics of cyclophosphamide, and possibly monitoring the pharmacokinetics of cyclophosphamide in individuals, may be useful for improving its therapeutic index. Cyclophosphamide is an extensively used anticancer and immunosuppressive agent.
Cyclophosphamide: Uses, Interactions, Mechanism of Action
Pharmacology Indication. Cyclophosphamide for intravenous injection is indicated for the treatment of a number of malignancies, including: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary ...
Clinical pharmacokinetics of cyclophosphamide - PubMed
Cyclophosphamide is used in doses that range from 1.5 to 60 mg/kg/day. A steep dose-response curve exists, and reductions in dose can lead to unfavourable outcomes. Myelosuppression is the dose-limiting toxicity, although in the setting of bone marrow transplantation, escalation beyond that dosage range is limited by cardiac toxicity.
Clinical Pharmacokinetics of Cyclophosphamide - Springer
2012年11月9日 · Sensitive and specific methods are now available for the measurement of cyclophosphamide, its metabolites and its stereoisomers in plasma and urine. The pharmacokinetics of cyclophosphamide have been understood for many years; those of the cytotoxic metabolites have been described more recently.
Single-Dose Pharmacokinetics and Total Removal of Cyclophosphamide …
2023年7月13日 · Thus, we aimed to readdress the pharmacokinetics of cyclophosphamide in a patient suffering from AAV using both, intermittent (IHD) and prolonged intermittent kidney replacement therapy (PIKRT) due to AKI on CKD.
Clinical Pharmacokinetics of Cyclophosphamide - Springer
2012年9月30日 · The current knowledge on the pharmacokinetics of cyclophosphamide and the (potential) relationships between exposure to cyclophosphamide metabolites and efficacy and toxicity, may enable us to design cyclophosphamide administrations for obtaining optimal effect of …
Population pharmacokinetics of cyclophosphamide and its …
Using NONMEM, an integrated population pharmacokinetic model was used to describe the pharmacokinetics of CP, 4OHCP, 2DCECP, and PM, including the already described processes of autoinduction of CP and the interaction with thiotepa.
Clinical Pharmacokinetics of Cyclophosphamide - Springer
2012年12月13日 · At least 80% of an administered dose of cyclophosphamide is eliminated by metabolism. Both cyclophosphamide and metabolites are principally excreted by the kidney. Renal clearance has been measured at 5 to 11 ml/min, suggesting extensive tubular resorption; up to 25% of the administered dose is excreted unchanged in the first 24 hours.
Association of cyclophosphamide pharmacokinetics to …
2005年8月23日 · In the present study, the pharmacokinetics of CP were determined in 60 patients using a linear and a population pharmacokinetic model to analyze the effects of defined genotypes of the cytochrome...
Cyclophosphamide pharmacokinetics and dose requirements …
2001年8月29日 · Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Background Intravenous pulse administration of cyclophosphamide (CYC) has been successfully used for the treatment of various autoimmune diseases.